Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Stifel argues sympathy trading not a predictor for Viking's pending VK2735 data » 10:28
03/22/23
03/22
10:28
03/22/23
10:28
VKTX

Viking Therapeutics

$9.56 /

+0.18 (+1.92%)

, ALT

Altimmune

$4.55 /

-0.4 (-8.08%)

, LLY

Eli Lilly

$335.15 /

+4.15 (+1.25%)

Viking Therapeutics…

Viking Therapeutics (VKTX) shares traded down ~20% following the Phase 2 interim data of pemvidutide announced by Altimmune (ALT), a competing GLP-1/glucagon program in obesity, Stifel tells investors in a research note. The firm believes this reaction is undeserved due to it being a different compound altogether. Further, Stifel argues a better benchmark for comparison is Eli Lilly's (LLY) Mounjaro. Viking's VK2735 is approaching Phase 1b SAD/MAD data before the end of Q1, which the firm believes will serve to set safety/tolerability expectations and elucidate points of differentiation. Stifel reiterated a Buy rating and a $22 price target on the stock.

ShowHide Related Items >><<
VKTX Viking Therapeutics
$9.56 /

+0.18 (+1.92%)

LLY Eli Lilly
$335.15 /

+4.15 (+1.25%)

ALT Altimmune
$4.55 /

-0.4 (-8.08%)

VKTX Viking Therapeutics
$9.56 /

+0.18 (+1.92%)

03/21/23 William Blair
William Blair says Viking bull thesis intact after Altimmune data
03/16/23 Stifel
Viking Therapeutics initiated with a Buy at Stifel
02/23/23 Oppenheimer
Viking Therapeutics price target raised to $20 from $17 at Oppenheimer
01/16/23 Piper Sandler
Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler
ALT Altimmune
$4.55 /

-0.4 (-8.08%)

03/21/23 Goldman Sachs
Altimmune downgraded to Neutral from Buy at Goldman Sachs
03/21/23 H.C. Wainwright
Altimmune attractive after 'overdone' selloff, says H.C. Wainwright
03/21/23 H.C. Wainwright
Altimmune selloff on weight loss data overdone, says H.C. Wainwright
LLY Eli Lilly
$335.15 /

+4.15 (+1.25%)

03/17/23 Stifel
Stifel trims Biogen target, but has more confidence lecanemab 'best-in-class'
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight on recent selloff at Wells Fargo
03/13/23 Wells Fargo
Eli Lilly upgraded to Overweight from Equal Weight at Wells Fargo
03/09/23 JPMorgan
Eli Lilly weakness brings attractive entry point, says JPMorgan
VKTX Viking Therapeutics
$9.56 /

+0.18 (+1.92%)

LLY Eli Lilly
$335.15 /

+4.15 (+1.25%)

ALT Altimmune
$4.55 /

-0.4 (-8.08%)

VKTX Viking Therapeutics
$9.56 /

+0.18 (+1.92%)

LLY Eli Lilly
$335.15 /

+4.15 (+1.25%)

VKTX Viking Therapeutics
$9.56 /

+0.18 (+1.92%)

LLY Eli Lilly
$335.15 /

+4.15 (+1.25%)

ALT Altimmune
$4.55 /

-0.4 (-8.08%)

VKTX Viking Therapeutics
$9.56 /

+0.18 (+1.92%)

LLY Eli Lilly
$335.15 /

+4.15 (+1.25%)

ALT Altimmune
$4.55 /

-0.4 (-8.08%)

Tuesday
Recommendations
William Blair says Viking bull thesis intact after Altimmune data » 16:22
03/21/23
03/21
16:22
03/21/23
16:22
VKTX

Viking Therapeutics

$9.38 /

-2.24 (-19.28%)

, ALT

Altimmune

$4.95 /

-5.97 (-54.67%)

Shares of Viking…

Shares of Viking Therapeutics (VKTX) trading down on concerns stemming from Altimmune's (ALT) "underwhelming" date this morning, William Blair the analyst tells investors in a research note. The analyst emphasizes that Viking's VK2735 is a dual GLP-1/GIP agonist on track to have first-in-human data in obese individuals later this morning or in April. In contrast, Altimmune's pemvidutide is a dual GLP-1/glucagon receptor agonist with a different mechanism of action, and therefore has limited read-through to Viking. In addition, Blair says the bullish thesis on Viking remains on its non-alcoholic steatohepatitis asset, VK2809. It is a buyer of the stock on the selloff and keeps an Outperform rating on the name.

ShowHide Related Items >><<
VKTX Viking Therapeutics
$9.38 /

-2.24 (-19.28%)

ALT Altimmune
$4.95 /

-5.97 (-54.67%)

VKTX Viking Therapeutics
$9.38 /

-2.24 (-19.28%)

03/16/23 Stifel
Viking Therapeutics initiated with a Buy at Stifel
02/23/23 Oppenheimer
Viking Therapeutics price target raised to $20 from $17 at Oppenheimer
01/16/23 Piper Sandler
Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler
12/20/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
ALT Altimmune
$4.95 /

-5.97 (-54.67%)

03/21/23 H.C. Wainwright
Altimmune attractive after 'overdone' selloff, says H.C. Wainwright
03/21/23 H.C. Wainwright
Altimmune selloff on weight loss data overdone, says H.C. Wainwright
03/21/23 JMP Securities
Altimmune's Pemvi 'at least as good' as semaglutide, says JMP Securities
02/28/23 B. Riley
B. Riley keeps Buy rating on Altimmune after Q4 results, pipeline updates
VKTX Viking Therapeutics
$9.38 /

-2.24 (-19.28%)

ALT Altimmune
$4.95 /

-5.97 (-54.67%)

VKTX Viking Therapeutics
$9.38 /

-2.24 (-19.28%)

VKTX Viking Therapeutics
$9.38 /

-2.24 (-19.28%)

ALT Altimmune
$4.95 /

-5.97 (-54.67%)

VKTX Viking Therapeutics
$9.38 /

-2.24 (-19.28%)

ALT Altimmune
$4.95 /

-5.97 (-54.67%)

Options
Viking Therapeutics call volume above normal and directionally bullish » 15:45
03/21/23
03/21
15:45
03/21/23
15:45
VKTX

Viking Therapeutics

$9.43 /

-2.19 (-18.85%)

Bullish option flow…

Bullish option flow detected in Viking Therapeutics with 13,311 calls trading, 4x expected, and implied vol increasing almost 38 points to 132.00%. Apr-23 14 calls and Apr-23 15 calls are the most active options, with total volume in those strikes near 3,600 contracts. The Put/Call Ratio is 0.35. Earnings are expected on April 26th.

ShowHide Related Items >><<
VKTX Viking Therapeutics
$9.43 /

-2.19 (-18.85%)

VKTX Viking Therapeutics
$9.43 /

-2.19 (-18.85%)

03/16/23 Stifel
Viking Therapeutics initiated with a Buy at Stifel
02/23/23 Oppenheimer
Viking Therapeutics price target raised to $20 from $17 at Oppenheimer
01/16/23 Piper Sandler
Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler
12/20/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
VKTX Viking Therapeutics
$9.43 /

-2.19 (-18.85%)

VKTX Viking Therapeutics
$9.43 /

-2.19 (-18.85%)

VKTX Viking Therapeutics
$9.43 /

-2.19 (-18.85%)

VKTX Viking Therapeutics
$9.43 /

-2.19 (-18.85%)

Over a week ago
Initiation
Viking Therapeutics initiated with a Buy at Stifel » 16:10
03/16/23
03/16
16:10
03/16/23
16:10
VKTX

Viking Therapeutics

$10.96 /

+0.25 (+2.33%)

Stifel analyst Annabel…

Stifel analyst Annabel Samimy initiated coverage of Viking Therapeutics with a Buy rating and $22 price target, telling investors that the firm views the stock as "a stronger value proposition to play the NASH and obesity markets." VK2809 is approaching Phase 2b data with "a strong early profile of liver fat reduction, proven correlation with NASH/fibrosis reduction, and highly specific liver targeting that could offer better tolerability," the firm said.

ShowHide Related Items >><<
VKTX Viking Therapeutics
$10.96 /

+0.25 (+2.33%)

VKTX Viking Therapeutics
$10.96 /

+0.25 (+2.33%)

02/23/23 Oppenheimer
Viking Therapeutics price target raised to $20 from $17 at Oppenheimer
01/16/23 Piper Sandler
Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler
12/20/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
12/19/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
VKTX Viking Therapeutics
$10.96 /

+0.25 (+2.33%)

VKTX Viking Therapeutics
$10.96 /

+0.25 (+2.33%)

VKTX Viking Therapeutics
$10.96 /

+0.25 (+2.33%)

VKTX Viking Therapeutics
$10.96 /

+0.25 (+2.33%)

Options
Viking Therapeutics call volume above normal and directionally bullish » 11:25
03/16/23
03/16
11:25
03/16/23
11:25
VKTX

Viking Therapeutics

$10.60 /

-0.11 (-1.03%)

Bullish option flow…

Bullish option flow detected in Viking Therapeutics with 3,290 calls trading, 2x expected, and implied vol increasing almost 3 points to 92.34%. Apr-23 16 calls and Mar-23 11 calls are the most active options, with total volume in those strikes near 2,300 contracts. The Put/Call Ratio is 0.06. Earnings are expected on April 26th.

ShowHide Related Items >><<
VKTX Viking Therapeutics
$10.60 /

-0.11 (-1.03%)

VKTX Viking Therapeutics
$10.60 /

-0.11 (-1.03%)

02/23/23 Oppenheimer
Viking Therapeutics price target raised to $20 from $17 at Oppenheimer
01/16/23 Piper Sandler
Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler
12/20/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
12/19/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
VKTX Viking Therapeutics
$10.60 /

-0.11 (-1.03%)

VKTX Viking Therapeutics
$10.60 /

-0.11 (-1.03%)

VKTX Viking Therapeutics
$10.60 /

-0.11 (-1.03%)

VKTX Viking Therapeutics
$10.60 /

-0.11 (-1.03%)

Options
Viking Therapeutics call volume above normal and directionally bullish » 15:45
03/08/23
03/08
15:45
03/08/23
15:45
VKTX

Viking Therapeutics

$11.45 /

+0.1 (+0.88%)

Bullish option flow…

Bullish option flow detected in Viking Therapeutics with 5,327 calls trading, 1.1x expected, and implied vol increasing over 10 points to 82.49%. Mar-23 13 calls and Mar-23 12 calls are the most active options, with total volume in those strikes near 4,300 contracts. The Put/Call Ratio is 0.05. Earnings are expected on April 26th.

ShowHide Related Items >><<
VKTX Viking Therapeutics
$11.45 /

+0.1 (+0.88%)

VKTX Viking Therapeutics
$11.45 /

+0.1 (+0.88%)

02/23/23 Oppenheimer
Viking Therapeutics price target raised to $20 from $17 at Oppenheimer
01/16/23 Piper Sandler
Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler
12/20/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
12/19/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
VKTX Viking Therapeutics
$11.45 /

+0.1 (+0.88%)

VKTX Viking Therapeutics
$11.45 /

+0.1 (+0.88%)

VKTX Viking Therapeutics
$11.45 /

+0.1 (+0.88%)

VKTX Viking Therapeutics
$11.45 /

+0.1 (+0.88%)

Conference/Events
William Blair biotech analysts to hold an analyst/industry conference call » 11:25
02/24/23
02/24
11:25
02/24/23
11:25
VKTX

Viking Therapeutics

$11.26 /

-0.19 (-1.66%)

Biotechnology Analyst…

Biotechnology Analyst Hsieh provides a preview of the upcoming first-in-human data of VK2735, the dual GLP-1/GIP agonist from Viking Therapeutics on an Analyst/Industry conference call to be held on February 24 at 12 pm. Webcast Link

ShowHide Related Items >><<
VKTX Viking Therapeutics
$11.26 /

-0.19 (-1.66%)

VKTX Viking Therapeutics
$11.26 /

-0.19 (-1.66%)

02/23/23 Oppenheimer
Viking Therapeutics price target raised to $20 from $17 at Oppenheimer
01/16/23 Piper Sandler
Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler
12/20/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
12/19/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
VKTX Viking Therapeutics
$11.26 /

-0.19 (-1.66%)

VKTX Viking Therapeutics
$11.26 /

-0.19 (-1.66%)

VKTX Viking Therapeutics
$11.26 /

-0.19 (-1.66%)

VKTX Viking Therapeutics
$11.26 /

-0.19 (-1.66%)

Conference/Events
William Blair biotech analysts to hold an analyst/industry conference call » 04:55
02/24/23
02/24
04:55
02/24/23
04:55
VKTX

Viking Therapeutics

$11.44 /

+0.435 (+3.95%)

Biotechnology Analyst…

Biotechnology Analyst Hsieh provides a preview of the upcoming first-in-human data of VK2735, the dual GLP-1/GIP agonist from Viking Therapeutics on an Analyst/Industry conference call to be held on February 24 at 12 pm. Webcast Link

ShowHide Related Items >><<
VKTX Viking Therapeutics
$11.44 /

+0.435 (+3.95%)

VKTX Viking Therapeutics
$11.44 /

+0.435 (+3.95%)

02/23/23 Oppenheimer
Viking Therapeutics price target raised to $20 from $17 at Oppenheimer
01/16/23 Piper Sandler
Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler
12/20/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
12/19/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
VKTX Viking Therapeutics
$11.44 /

+0.435 (+3.95%)

VKTX Viking Therapeutics
$11.44 /

+0.435 (+3.95%)

VKTX Viking Therapeutics
$11.44 /

+0.435 (+3.95%)

VKTX Viking Therapeutics
$11.44 /

+0.435 (+3.95%)

Conference/Events
William Blair biotech analysts to hold an analyst/industry conference call » 16:11
02/23/23
02/23
16:11
02/23/23
16:11
VKTX

Viking Therapeutics

$11.45 /

+0.445 (+4.04%)

Biotechnology Analyst…

Biotechnology Analyst Hsieh provides a preview of the upcoming first-in-human data of VK2735, the dual GLP-1/GIP agonist from Viking Therapeutics on an Analyst/Industry conference call to be held on February 24 at 12 pm. Webcast Link

ShowHide Related Items >><<
VKTX Viking Therapeutics
$11.45 /

+0.445 (+4.04%)

VKTX Viking Therapeutics
$11.45 /

+0.445 (+4.04%)

02/23/23 Oppenheimer
Viking Therapeutics price target raised to $20 from $17 at Oppenheimer
01/16/23 Piper Sandler
Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler
12/20/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
12/19/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
VKTX Viking Therapeutics
$11.45 /

+0.445 (+4.04%)

VKTX Viking Therapeutics
$11.45 /

+0.445 (+4.04%)

VKTX Viking Therapeutics
$11.45 /

+0.445 (+4.04%)

VKTX Viking Therapeutics
$11.45 /

+0.445 (+4.04%)

Recommendations
Viking Therapeutics price target raised to $20 from $17 at Oppenheimer » 11:54
02/23/23
02/23
11:54
02/23/23
11:54
VKTX

Viking Therapeutics

$11.40 /

+0.395 (+3.59%)

Oppenheimer analyst Jay…

Oppenheimer analyst Jay Olson raised the firm's price target on Viking Therapeutics to $20 from $17 and keeps an Outperform rating on the shares. The firm views VK2735 as an underappreciated asset for Viking with a large potential opportunity in obesity. Oppenheimer added that it believes the Phase 1 data for VK2735 expected in Q1 could unlock substantial shareholder value, and its scenario analysis forecasts +20% probability-weighted upside.

ShowHide Related Items >><<
VKTX Viking Therapeutics
$11.40 /

+0.395 (+3.59%)

VKTX Viking Therapeutics
$11.40 /

+0.395 (+3.59%)

01/16/23 Piper Sandler
Aligos Therapeutics price target raised to $7 from $3 at Piper Sandler
12/20/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
12/19/22 Maxim
Viking Therapeutics price target raised to $15 from $10 at Maxim
12/19/22 Raymond James
Raymond James upgrades Madrigal to Market Perform after NASH data
VKTX Viking Therapeutics
$11.40 /

+0.395 (+3.59%)

VKTX Viking Therapeutics
$11.40 /

+0.395 (+3.59%)

VKTX Viking Therapeutics
$11.40 /

+0.395 (+3.59%)

VKTX Viking Therapeutics
$11.40 /

+0.395 (+3.59%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.